GLPG0634 DARWIN 1 study to deliver 12 week topline data in Q1 2015 GLPG0974 shows biomarker effect & good safety in ulcerative colitis patients, but lacks clinical improvement in 4 week Proof-of-Concept study GLPG1492 mode of action scalable to ESKAPE and other pathogens Multiple Phase 2 readouts with novel modes-of-action in coming two years Live ... (more)
More...
More...